Frontiers in Oncology (Jul 2022)

Cost-Effectiveness of BRCA 1/2 Genetic Test and Preventive Strategies: Using Real-World Data From an Upper-Middle Income Country

  • Marina Lourenção,
  • Marina Lourenção,
  • Julia Simões Correa Galendi,
  • Henrique de Campos Reis Galvão,
  • Augusto Perazzolo Antoniazzi,
  • Rebeca Silveira Grasel,
  • Rebeca Silveira Grasel,
  • André Lopes Carvalho,
  • Edmundo Carvalho Mauad,
  • Jorge Henrique Caldeira de Oliveira,
  • Rui Manuel Reis,
  • Rui Manuel Reis,
  • Rui Manuel Reis,
  • Olena Mandrik,
  • Edenir Inêz Palmero,
  • Edenir Inêz Palmero

DOI
https://doi.org/10.3389/fonc.2022.951310
Journal volume & issue
Vol. 12

Abstract

Read online

Although BRCA1/2 genetic testing in developed countries is part of the reality for high-risk patients for hereditary breast and ovarian cancer (HBOC), the same is not true for upper-middle-income countries. For that reason, this study aimed to evaluate whether the BRCA1/2 genetic test and preventive strategies for women at high risk for HBOC are cost-effective compared to not performing these strategies in an upper-middle-income country. Adopting a payer perspective, a Markov model with a time horizon of 70 years was built to delineate the health states for a cohort of healthy women aged 30 years that fulfilled the BRCA1/2 testing criteria according to the guidelines. Transition probabilities were calculated based on real-world data of women tested for BRCA1/2 germline mutations in a cancer reference hospital from 2011 to 2020. We analyzed 275 BRCA mutated index cases and 356 BRCA mutation carriers that were first- or second-degree relatives of the patients. Costs were based on the Brazilian public health system reimbursement values. Health state utilities were retrieved from literature. The BRCA1/2 genetic test and preventive strategies result in more quality-adjusted life years (QALYs) and costs with an incremental cost-effectiveness ratio of R$ 11,900.31 (U$ 5,504.31)/QALY. This result can represent a strong argument in favor of implementing genetic testing strategies for high-risk women even in countries with upper-middle income, considering not only the cancer prevention possibilities associated with the genetic testing but also its cost-effectiveness to the health system. These strategies are cost-effective, considering a willingness-to-pay threshold of R$ 25,000 (U$ 11,563.37)/QALY, indicating that the government should consider offering them for women at high risk for HBOC. The results were robust in deterministic and probabilistic sensitivity analyses.

Keywords